Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Pharmaceutical CDMO Market, 2019-2030, $ bn 19
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical CDMO Market 25
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical CDMO Market 30
Figure 9. Investment Opportunity Analysis 34
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical CDMO Market 37
Figure 11. Breakdown of North America Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue 41
Figure 12. North America Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 42
Figure 13. North America Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn 43
Figure 14. North America Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn 44
Figure 15. Breakdown of North America Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue 45
Figure 16. North America Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%) 46
Figure 17. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn 47
Figure 18. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 48
Figure 19. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 49
Figure 20. North America Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn 51
Figure 21. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn 52
Figure 22. North America Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn 54
Figure 23. North America Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn 55
Figure 24. North America Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn 56
Figure 25. North America Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn 57
Figure 26. North America Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn 58
Figure 27. North America Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn 59
Figure 28. North America Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn 60
Figure 29. North America Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn 61
Figure 30. Breakdown of North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue 63
Figure 31. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 63
Figure 32. North America Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn 64
Figure 33. North America Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn 65
Figure 34. North America Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn 66
Figure 35. North America Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn 67
Figure 36. North America Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn 68
Figure 37. North America Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn 69
Figure 38. North America Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn 70
Figure 39. North America Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn 71
Figure 40. Breakdown of North America Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue 72
Figure 41. North America Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%) 73
Figure 42. North America Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn 74
Figure 43. North America Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn 75
Figure 44. North America Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn 76
Figure 45. Breakdown of North America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue 78
Figure 46. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 79
Figure 47. U.S. Pharmaceutical CDMO Market, 2019-2030, $ bn 81
Figure 48. Canada Pharmaceutical CDMO Market, 2019-2030, $ bn 84
Figure 49. Pharmaceutical CDMO Market in Mexico, 2015-2030, $ bn 86
Figure 50. Growth Stage of North America Pharmaceutical CDMO Industry over the Forecast Period 88
North America pharmaceutical CDMO market is expected to grow by 6.0% annually in the forecast period and reach $101.1 billion by 2030 driven by increasing demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures. Highlighted with 37 tables and 50 figures, this 131-page report “North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on a comprehensive research of the entire North America pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country. Based on Category, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Pharmaceutical Contract Manufacturing Organization (CMO) • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing) • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs) • Secondary Packaging Pharmaceutical Contract Research Organization (CRO) • CRO for Pre-clinical Development • CRO for Phase I Trials • CRO for Phase II Trials • CRO for Phase III Trials • CRO for Phase IV Trials • Laboratory Services • Consulting Services • Data Management Services Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical & Biopharmaceutical Companies • Medical Device Companies • Academic Institutes Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Company Profiles of CMO: Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH 8.3.2 Company Profiles of CRO: Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co Ltd ICON Plc IQVIA Holdings Inc. LSK North America Pharma Service Co Ltd Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co. Ltd SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More